IOVANCE BIOTHERAPEUTICS, INC. Impairment of Long-Lived Assets Held-for-use
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Impairment of Long-Lived Assets Held-for-use of $7.36 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2025-02-27
- IOVANCE BIOTHERAPEUTICS, INC. impairment of long-lived assets held-for-use for the quarter ending 2023-09-30 was $0.00.
- IOVANCE BIOTHERAPEUTICS, INC. impairment of long-lived assets held-for-use for the quarter ending 2023-06-30 was $0.00.
- IOVANCE BIOTHERAPEUTICS, INC. impairment of long-lived assets held-for-use for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. impairment of long-lived assets held-for-use for the quarter ending 2022-12-31 was $83.00K.
- IOVANCE BIOTHERAPEUTICS, INC. impairment of long-lived assets held-for-use for fiscal 2024 was $7.36M.
- IOVANCE BIOTHERAPEUTICS, INC. impairment of long-lived assets held-for-use for fiscal 2022 was $397.00K.
- IOVANCE BIOTHERAPEUTICS, INC. impairment of long-lived assets held-for-use for fiscal 2021 was $0.00.
- IOVANCE BIOTHERAPEUTICS, INC. impairment of long-lived assets held-for-use for fiscal 2020 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 12 month | Impairment of Long-Lived Assets Held-for-use 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $7.36M 10-K · filed 2025-02-27 | ||||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | $83.00K derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | $83.00K derived: sum of 3 quarters · filed 2025-02-27 | $83.00K derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-10 | $83.00K derived: sum of 2 quarters · filed 2025-02-27 | $83.00K derived: sum of 3 quarters · filed 2025-02-27 | $83.00K derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $83.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $83.00K derived: sum of 2 quarters · filed 2025-02-27 | $83.00K derived: sum of 3 quarters · filed 2025-02-27 | $397.00K 10-K · filed 2025-02-27 | $0.00 10-K · filed 2023-02-28 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $314.00K 10-Q · filed 2023-11-07 | $314.00K derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $314.00K 10-Q · filed 2023-08-08 | $314.00K derived: sum of 3 quarters · filed 2023-08-08 | $314.00K derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | $314.00K 10-Q · filed 2023-05-10 | $314.00K derived: sum of 2 quarters · filed 2023-05-10 | $314.00K derived: sum of 3 quarters · filed 2023-05-10 | $314.00K derived: sum of 4 quarters · filed 2023-05-10 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | ||||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 | ||||
| 2019-12-31 | $0.00 10-K · filed 2022-02-24 | ||||
| 2018-12-31 | $0.00 10-K · filed 2021-02-25 | ||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |